MX2009005753A - Modulacion de trayectorias metabolicas de prostaglandina/ciclooxig enasa. - Google Patents
Modulacion de trayectorias metabolicas de prostaglandina/ciclooxig enasa.Info
- Publication number
- MX2009005753A MX2009005753A MX2009005753A MX2009005753A MX2009005753A MX 2009005753 A MX2009005753 A MX 2009005753A MX 2009005753 A MX2009005753 A MX 2009005753A MX 2009005753 A MX2009005753 A MX 2009005753A MX 2009005753 A MX2009005753 A MX 2009005753A
- Authority
- MX
- Mexico
- Prior art keywords
- prostaglandin
- metabolic pathways
- cyclooxygenase
- modulation
- diseases
- Prior art date
Links
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 title abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 title abstract 2
- 230000037353 metabolic pathway Effects 0.000 title abstract 2
- 150000003180 prostaglandins Chemical class 0.000 title abstract 2
- AWSUSADYFDCYML-KUPUPYBPSA-N (z)-7-[(1s,5r)-5-[(e)-oct-1-enyl]-4-oxocyclopent-2-en-1-yl]hept-5-enoic acid Chemical compound CCCCCC\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O AWSUSADYFDCYML-KUPUPYBPSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 208000020431 spinal cord injury Diseases 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86787306P | 2006-11-30 | 2006-11-30 | |
| GB0623971A GB0623971D0 (en) | 2006-11-30 | 2006-11-30 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
| PCT/GB2007/004584 WO2008065408A2 (en) | 2006-11-30 | 2007-11-29 | Modulation of prostaglandin/cyclooxygenase metabolic pathways |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009005753A true MX2009005753A (es) | 2009-09-28 |
Family
ID=39381924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009005753A MX2009005753A (es) | 2006-11-30 | 2007-11-29 | Modulacion de trayectorias metabolicas de prostaglandina/ciclooxig enasa. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100137270A1 (https=) |
| EP (2) | EP2097079B1 (https=) |
| JP (1) | JP2010511028A (https=) |
| KR (1) | KR20090086272A (https=) |
| AU (1) | AU2007327011A1 (https=) |
| CA (1) | CA2670957A1 (https=) |
| HR (1) | HRP20120687T1 (https=) |
| IL (1) | IL199013A0 (https=) |
| MX (1) | MX2009005753A (https=) |
| NO (1) | NO20092455L (https=) |
| PL (1) | PL2097079T3 (https=) |
| TW (1) | TWI414298B (https=) |
| WO (1) | WO2008065408A2 (https=) |
| ZA (1) | ZA200903584B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| GB0523550D0 (en) | 2005-11-18 | 2005-12-28 | Hunter Fleming Ltd | Therapeutic uses of steroidal compounds |
| WO2013120851A1 (en) * | 2012-02-13 | 2013-08-22 | Mach-3D Sàrl | Method for sharing emotions through the creation of three-dimensional avatars and their interaction through a cloud-based platform |
| US9328060B2 (en) | 2013-10-18 | 2016-05-03 | East Carolina University | J-series prostaglandin-ethanolamides as novel therapeutics |
| JP6917631B2 (ja) * | 2016-02-15 | 2021-08-11 | 学校法人近畿大学 | 抗不安作用を有する医薬組成物および加工食品 |
| WO2023060107A1 (en) * | 2021-10-05 | 2023-04-13 | University Of South Florida | Compositions and uses thereof for treatment of neurological disorders |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7100213A (en) * | 1971-01-08 | 1972-07-11 | 1,2,3,4-tetrahydrocarbazole derivs - anti-inflammatories | |
| FR2696934B1 (fr) * | 1992-10-20 | 1995-06-02 | Conservatoire Nal Arts Metiers | Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir. |
| US5451600A (en) * | 1994-04-19 | 1995-09-19 | Hoffmann-La Roche Inc. | Substituted tetrahydrobenzopyrrolylfuranoic acid derivatives as phospholipase A2 inhibitors |
| EP0906090A1 (en) * | 1996-03-15 | 1999-04-07 | Somerset Pharmaceuticals, Inc. | Method for preventing and treating peripheral neurophathy by administering selegiline |
| WO2000006560A1 (en) * | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
| US20030083231A1 (en) * | 1998-11-24 | 2003-05-01 | Ahlem Clarence N. | Blood cell deficiency treatment method |
| US6667299B1 (en) * | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US20030060425A1 (en) * | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| GB0003524D0 (en) * | 2000-02-15 | 2000-04-05 | Btg Int Ltd | Cytoprotective steroids (II) |
| GB2363984A (en) * | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids |
| GB2363983A (en) | 2000-06-29 | 2002-01-16 | Hunter Fleming Ltd | Protection against neuronal damage using 7-hydroxyepiandrosterone |
| AU780173B2 (en) | 2000-08-25 | 2005-03-03 | Michael John Till | Sampling device |
| WO2002069977A1 (en) * | 2001-03-01 | 2002-09-12 | Hollis-Eden Pharmaceuticals, Inc. | Use of certain steroids for treatment of blood cell deficiencies |
| SE0100857D0 (sv) * | 2001-03-13 | 2001-03-13 | Tomas Hagstroem | Treatment of tumors |
| GB2378898A (en) * | 2001-08-14 | 2003-02-26 | Hunter Fleming Ltd | Prophylactic and therapeutic use of hydroxysteroids |
| FR2829697B1 (fr) * | 2001-09-14 | 2004-03-19 | Mayoly Spindler Lab | Derives 7-hydroxyles et 7-cetoniques des hormones steroides 3 beta-hydroxylees pour le traitement des maladies inflammatoires ou fonctionnelles de l'intestin |
| GB0403889D0 (en) * | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| US20070231373A1 (en) * | 2004-04-28 | 2007-10-04 | Hunter-Fleming Limited | Transdermal Steriod for Formulation |
| GB2422828A (en) * | 2005-02-03 | 2006-08-09 | Hunter Fleming Ltd | Tricyclic cytoprotective compounds comprising an indole residue |
| US20060234993A1 (en) * | 2005-04-13 | 2006-10-19 | Eric Marchewitz | Use of androstane derivatives for enhancing physical performance |
-
2007
- 2007-11-29 WO PCT/GB2007/004584 patent/WO2008065408A2/en not_active Ceased
- 2007-11-29 CA CA002670957A patent/CA2670957A1/en not_active Abandoned
- 2007-11-29 JP JP2009538785A patent/JP2010511028A/ja active Pending
- 2007-11-29 AU AU2007327011A patent/AU2007327011A1/en not_active Abandoned
- 2007-11-29 EP EP07870407A patent/EP2097079B1/en active Active
- 2007-11-29 MX MX2009005753A patent/MX2009005753A/es active IP Right Grant
- 2007-11-29 KR KR1020097013708A patent/KR20090086272A/ko not_active Ceased
- 2007-11-29 EP EP09012181A patent/EP2147673A1/en not_active Withdrawn
- 2007-11-29 HR HRP20120687TT patent/HRP20120687T1/hr unknown
- 2007-11-29 US US12/516,772 patent/US20100137270A1/en not_active Abandoned
- 2007-11-29 PL PL07870407T patent/PL2097079T3/pl unknown
- 2007-11-30 TW TW096145663A patent/TWI414298B/zh not_active IP Right Cessation
-
2009
- 2009-05-22 ZA ZA2009/03584A patent/ZA200903584B/en unknown
- 2009-05-27 IL IL199013A patent/IL199013A0/en unknown
- 2009-06-29 NO NO20092455A patent/NO20092455L/no not_active Application Discontinuation
-
2012
- 2012-08-03 US US13/566,136 patent/US20130023504A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20130023504A1 (en) | 2013-01-24 |
| WO2008065408A2 (en) | 2008-06-05 |
| WO2008065408A9 (en) | 2011-03-03 |
| US20100137270A1 (en) | 2010-06-03 |
| KR20090086272A (ko) | 2009-08-11 |
| NO20092455L (no) | 2009-08-14 |
| CA2670957A1 (en) | 2008-06-05 |
| TWI414298B (zh) | 2013-11-11 |
| WO2008065408A3 (en) | 2008-11-20 |
| HRP20120687T1 (hr) | 2012-09-30 |
| AU2007327011A1 (en) | 2008-06-05 |
| EP2097079A2 (en) | 2009-09-09 |
| EP2147673A1 (en) | 2010-01-27 |
| ZA200903584B (en) | 2010-11-24 |
| TW200831108A (en) | 2008-08-01 |
| EP2097079B1 (en) | 2012-06-27 |
| IL199013A0 (en) | 2010-02-17 |
| JP2010511028A (ja) | 2010-04-08 |
| PL2097079T3 (pl) | 2012-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY154462A (en) | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | |
| MX2009005753A (es) | Modulacion de trayectorias metabolicas de prostaglandina/ciclooxig enasa. | |
| WO2009120919A3 (en) | Fenofibrate dosage forms | |
| WO2008070692A3 (en) | Bicyclic compounds and use as antidiabetics | |
| EP2261216A3 (en) | Pyrazoles as glucokinase activators | |
| WO2007127505A3 (en) | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system | |
| WO2009068659A3 (en) | Novel disease treatment by predicting drug association | |
| WO2007149865A3 (en) | Methods and compositions related to inhibition of ceramide synthesis | |
| UA91895C2 (en) | Thiazole compounds and methods of use | |
| WO2009067493A3 (en) | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders | |
| MX2010004965A (es) | Derivados de amida como moduladores de la sirtuina. | |
| WO2009011871A3 (en) | Thiadiazole modulators of pkb | |
| CL2011001428A1 (es) | Compuestos derivados de amidas del acido tetrahidroisoquinolil-4-oxobutirico; composicion farmaceutica; y uso en el tratamiento de desordenes o enfermedades mediadas por canales de potasio kcnq2/3, tales como dolor, epilepsia. incontinencia urinaria, ansiedad, entre otras. | |
| WO2007020502A3 (en) | Cannabinoid receptor ligands and uses thereof | |
| IL177787A0 (en) | 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | |
| ATE493405T1 (de) | Pyrimidinylamidverbindungen, die die durch vla-4 vermittelte leukozytenadhäsion inhibieren | |
| WO2007133983A3 (en) | 2-aminobenzimidazoles for treating neurodegenerative diseases | |
| PL1828151T3 (pl) | Pochodne malonoamidów jako inhibitory gama-sekretazy do leczenia choroby alzheimera | |
| UY29777A1 (es) | Utilización de agomelatina para la obtención de medicamentos destinados al tratamiento de trastornos del sueno en pacientes con depresión. | |
| WO2008070311A3 (en) | Gene expression profiling of parkinson's disease | |
| TW200741205A (en) | A novel physiologically active compound, NESFATIN, related compounds thereof and their use | |
| BRPI0508560A (pt) | uso de antagonistas do receptor cb1 para a produção de uma composição útil para o tratamento de doenças hepáticas | |
| WO2005084368A3 (en) | Heteroalkyl-substituted biphenyl-4-carboxylic acid arylamide analogues | |
| MX2010004311A (es) | Productos intermedios de moduladores de gamma-secretasa. | |
| WO2007022642A3 (en) | Anti-inflammatory molecules and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HH | Correction or change in general | ||
| FG | Grant or registration |